https://terapiyacart.com/who-can-have-car-t-cell-therapy/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 Who can have CAR T-cell therapy? https://terapiyacart.com/what-are-the-differences-between-car-t-cell-therapy-and-other-cancer-therapies/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 What are the differences between CAR T-cell therapy and other cancer therapies? https://terapiyacart.com/what-are-t-cells-how-important-are-they/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 What are T cells? How important are they? https://terapiyacart.com/how-does-car-t-cell-therapy-find-cancer/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 How does CAR T-cell therapy find cancer? https://terapiyacart.com/what-are-tumor-markers-why-are-they-important-in-cancer-treatment/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 What are tumor markers? Why are they important in cancer treatment? https://terapiyacart.com/why-are-tumor-markers-important-in-car-t-cell-therapy/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 Why are tumor markers important in CAR T-cell therapy? https://terapiyacart.com/what-are-the-tumor-markers-in-blood-cancers-for-car-t-cell-therapy/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 What are the tumor markers in blood cancers for CAR T-cell therapy? https://terapiyacart.com/chinas-first-yescarta-is-the-first-approved-car-t-cell-therapy-in-the-country/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 China’s first! Yescarta is the first approved CAR T-cell therapy in the country https://terapiyacart.com/yescarta-is-now-available-in-macao/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 Yescarta is now available in Macao https://terapiyacart.com/new-indication-approved-to-carteyva-mantle-cell-lymphoma-mcl-is-now-treatable-in-china-with-car-t-cell-therapy/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 New indication approved to Carteyva. Mantle Cell Lymphoma (MCL) is now treatable in China with CAR T-cell therapy https://terapiyacart.com/case-report-complete-remission-lasting-over-2-years-after-car-t-treatment-in-a-high-risk-mantle-cell-lymphoma-patient/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 Case report: complete remission lasting over 2 years after car-t treatment in a high-risk mantle cell lymphoma patient https://terapiyacart.com/fosun-kites-car-t-second-line-indication-approved-opening-a-new-chapter-in-lymphoma-treatment/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 Yescarta second-line indication approved, opening a new chapter in lymphoma treatment https://terapiyacart.com/nmpa-approval-of-carteyva-in-patients-with-relapsed-or-refractory-follicular-lymphoma/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 NMPA approval of Carteyva in patients with relapsed or refractory follicular lymphoma https://terapiyacart.com/fucaso-approved-in-china-the-worlds-first-fully-human-bcma-car-t-cell-therapy-for-r-r-multiple-myeloma/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 Fucaso approved in China: The world’s first fully-human BCMA CAR T-cell therapy for r/r multiple myeloma https://terapiyacart.com/yorwida-cnct19-chinas-first-cd19-car-t-therapy-for-adult-b-all/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 Yorwida (CNCT19): China’s first CD19 CAR-T Therapy for Adult B-ALL https://terapiyacart.com/nmpa-approves-zevor-cel-for-relapsed-or-refractory-multiple-myeloma/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 NMPA approves Zevor-cel for relapsed or refractory multiple myeloma https://terapiyacart.com/carvykti-approved-in-china-for-relapsed-or-refractory-multiple-myeloma/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 Carvykti approved in China for relapsed or refractory multiple myeloma https://terapiyacart.com/which-car-t-cell-therapies-are-approved-in-china/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 Which CAR-T cell therapies are approved in China https://terapiyacart.com/latest-clinical-data-revealed-that-carvykti-has-significantly-extended-overall-survival-os-in-second-line-multiple-myeloma-patients/ 2026-08-28T12:56:13+08:00 ru 2026-08-28T12:56:13+08:00 Latest clinical data revealed that Carvykti has significantly extended overall survival OS in second-line multiple myeloma patients https://terapiyacart.com/becoming-a-car-t-patient-in-china/non-hodgkin-lymphoma/ 2026-08-28T12:56:12+08:00 ru 2026-08-28T12:56:12+08:00 Non-Hodgkin Lymphoma https://terapiyacart.com/becoming-a-car-t-patient-in-china/multiple-myeloma/ 2026-08-28T12:56:12+08:00 ru 2026-08-28T12:56:12+08:00 Multiple Myeloma https://terapiyacart.com/car-t-cell-therapy/managing-side-effects/ 2026-08-28T12:56:12+08:00 ru 2026-08-28T12:56:12+08:00 Managing Side Effects of CAR T Cell Therapy https://terapiyacart.com/car-t-cell-therapy/indications/ 2026-08-28T12:56:12+08:00 ru 2026-08-28T12:56:12+08:00 Indications https://terapiyacart.com/becoming-a-car-t-patient-in-china/gastroesophageal-junction-cancer/ 2026-08-28T12:56:12+08:00 ru 2026-08-28T12:56:12+08:00 Gastroesophageal Junction (GEJ) Cancer https://terapiyacart.com/becoming-a-car-t-patient-in-china/pancreatic-cancer/ 2026-08-28T12:56:12+08:00 ru 2026-08-28T12:56:12+08:00 Pancreatic Cancer https://terapiyacart.com/privacy-policy-2/ 2026-08-28T12:56:34+08:00 ru 2026-08-28T12:56:11+08:00 Privacy Policy https://terapiyacart.com/becoming-a-car-t-patient-in-china/leukemia/ 2026-08-28T12:56:33+08:00 ru 2026-08-28T12:56:10+08:00 Leukemia https://terapiyacart.com/solid-tumor/ 2026-08-28T12:56:34+08:00 ru 2026-08-28T12:56:10+08:00 Solid Tumor https://terapiyacart.com/why-china-is-the-best-country-for-car-t-cell-therapy/ 2026-08-28T12:56:34+08:00 ru 2026-08-28T12:56:10+08:00 Why China is the Best Country for CAR T Cell Therapy https://terapiyacart.com/car-t-options/yescarta/ 2026-08-28T12:56:34+08:00 ru 2026-08-28T12:56:10+08:00 Yescarta https://terapiyacart.com/car-t-cell-therapy/ 2026-08-28T12:56:34+08:00 ru 2026-08-28T12:56:10+08:00 CAR T Cell Therapy https://terapiyacart.com/contact-us/ 2026-08-28T12:56:34+08:00 ru 2026-08-28T12:56:10+08:00 Contact Us https://terapiyacart.com/ 2026-08-28T13:58:44+08:00 ru 2026-08-28T12:56:10+08:00 Home https://terapiyacart.com/car-t-options/fucaso/ 2026-08-28T12:56:33+08:00 ru 2026-08-28T12:56:09+08:00 Fucaso https://terapiyacart.com/car-t-options/carteyva/ 2026-08-28T12:56:33+08:00 ru 2026-08-28T12:56:09+08:00 Carteyva https://terapiyacart.com/car-t-options/yorwida/ 2026-08-28T12:56:33+08:00 ru 2026-08-28T12:56:08+08:00 Yorwida https://terapiyacart.com/car-t-options/zevor-cel/ 2026-08-28T12:56:33+08:00 ru 2026-08-28T12:56:07+08:00 Zevor-cel https://terapiyacart.com/car-t-options/ 2026-08-28T12:56:32+08:00 ru 2026-08-28T12:56:06+08:00 CAR-T Options https://terapiyacart.com/legal-disclaimer/ 2026-08-28T12:56:32+08:00 ru 2026-08-28T12:56:06+08:00 Legal Disclaimer https://terapiyacart.com/terms-conditions/ 2026-08-28T12:56:32+08:00 ru 2026-08-28T12:56:06+08:00 Terms & Conditions https://terapiyacart.com/car-t-options/carvykti/ 2026-08-28T12:56:33+08:00 ru 2026-08-28T12:56:06+08:00 Carvykti https://terapiyacart.com/car-t-cell-therapy/process-of-car-t-cell-therapy/ 2026-08-28T12:56:32+08:00 ru 2026-08-28T12:56:05+08:00 Process of CAR T Cell Therapy https://terapiyacart.com/becoming-a-car-t-patient-in-china/stomach-cancer/ 2026-08-28T12:56:32+08:00 ru 2026-08-28T12:56:05+08:00 Stomach Cancer https://terapiyacart.com/car-t-cell-therapy/who-is-eligible-for-car-t-cell-therapy/ 2026-08-28T12:56:32+08:00 ru 2026-08-28T12:56:05+08:00 Who Is Eligible For CAR-T Cell Therapy https://terapiyacart.com/becoming-a-car-t-patient-in-china/ 2026-08-28T12:56:31+08:00 ru 2026-08-28T12:56:04+08:00 Becoming A CAR-T Patient in China https://terapiyacart.com/news/ 2026-08-28T12:56:31+08:00 ru 2026-08-28T12:56:04+08:00 News https://terapiyacart.com/second-opinion/ 2026-08-28T12:56:31+08:00 ru 2026-08-28T12:56:04+08:00 Second Opinion https://terapiyacart.com/autoimmune-disease-treatment/systemic-lupus-erythematosus/ 2026-08-28T12:56:32+08:00 ru 2026-08-28T12:56:04+08:00 Systemic Lupus Erythematosus https://terapiyacart.com/autoimmune-disease-treatment/systemic-sclerosis/ 2026-08-28T12:56:32+08:00 ru 2026-08-28T12:56:04+08:00 Systemic Sclerosis https://terapiyacart.com/autoimmune-disease-treatment/ 2026-08-28T12:56:32+08:00 ru 2026-08-28T12:56:04+08:00 Autoimmune Disease Treatment https://terapiyacart.com/car-t-medical-centers/ 2026-08-28T12:56:30+08:00 ru 2026-08-28T12:56:03+08:00 CAR-T Medical Centers https://terapiyacart.com/becoming-a-car-t-patient-in-china/follicular-lymphoma/ 2026-08-28T12:56:30+08:00 ru 2026-08-28T12:56:03+08:00 Follicular Lymphoma https://terapiyacart.com/autoimmune-disease-treatment/multiple-sclerosis/ 2026-08-28T12:56:31+08:00 ru 2026-08-28T12:56:03+08:00 Multiple Sclerosis https://terapiyacart.com/becoming-a-car-t-patient-in-china/neuroblastoma/ 2026-08-28T12:56:31+08:00 ru 2026-08-28T12:56:03+08:00 Neuroblastoma https://terapiyacart.com/becoming-a-car-t-patient-in-china/glioblastoma/ 2026-08-28T12:56:31+08:00 ru 2026-08-28T12:56:03+08:00 Glioblastoma https://terapiyacart.com/car-t-options/carteyva/receiving-carteyva/ 2026-08-28T12:56:31+08:00 ru 2026-08-28T12:56:03+08:00 Receiving Carteyva https://terapiyacart.com/which-country-is-the-best-for-car-t-cell-therapy/ 2026-08-28T12:56:31+08:00 ru 2026-08-28T12:56:03+08:00 Which Country Is The Best For CAR-T Cell Therapy? https://terapiyacart.com/car-t-options/carteyva/is-carteyva-right-for-me/ 2026-08-28T12:56:31+08:00 ru 2026-08-28T12:56:03+08:00 Is Carteyva Right For Me? https://terapiyacart.com/car-t-medical-centers/beijing-gobroad-hospital/ 2026-08-28T12:56:30+08:00 ru 2026-08-28T12:56:02+08:00 Beijing GoBroad Hospital https://terapiyacart.com/car-t-medical-centers/ruijin-hospital/ 2026-08-28T12:56:30+08:00 ru 2026-08-28T12:56:02+08:00 Ruijin Hospital https://terapiyacart.com/car-t-options/claudin18-2-car-t-cell-therapy/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:56:00+08:00 Claudin18.2 CAR-T Cell Therapy https://terapiyacart.com/car-t-options/bcma-car-t-cell-therapy/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:56:00+08:00 BCMA CAR-T cell therapy https://terapiyacart.com/car-t-options/satri-cel/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:56:00+08:00 Satri-Cel https://terapiyacart.com/car-t-medical-centers/institute-of-hematology/ 2026-08-28T12:56:30+08:00 ru 2026-08-28T12:56:00+08:00 Institute of Hematology https://terapiyacart.com/car-t-medical-centers/beijing-boren-hospital/ 2026-08-28T12:56:30+08:00 ru 2026-08-28T12:56:00+08:00 Beijing Boren Hospital https://terapiyacart.com/becoming-a-car-t-patient-in-china/t-cell-lymphoma/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:59+08:00 T-cell Lymphoma https://terapiyacart.com/about-us/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:59+08:00 About Us https://terapiyacart.com/becoming-a-car-t-patient-in-china/large-b-cell-lymphoma/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:59+08:00 Large B-cell Lymphoma https://terapiyacart.com/becoming-a-car-t-patient-in-china/mantle-cell-lymphoma/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:59+08:00 Mantle Cell Lymphoma https://terapiyacart.com/car-t-options/cd19-car-t-cell-therapy/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:59+08:00 CD19 CAR-T Cell Therapy https://terapiyacart.com/carteyva-relmacabtagene-autoleucel-approved-in-china-for-large-b-cell-lymphoma-lbcl/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:59+08:00 Carteyva (relmacabtagene autoleucel) approved in China for large B-cell lymphoma (LBCL) https://terapiyacart.com/breakthrough-in-car-t-therapy-for-liver-cancer-first-patient-survives-nearly-5-years-cancer-free/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:59+08:00 Breakthrough in CAR-T Therapy for liver cancer: First patient survives nearly 5 years cancer-free https://terapiyacart.com/relma-cel-achieves-66-7-4-year-survival-in-r-r-lbcl-asco-2024-reports/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:58+08:00 Relma-cel Achieves 66.7% 4-Year Survival in R/R LBCL, ASCO 2024 Reports https://terapiyacart.com/car-t-cell-therapy-in-china-carteyva-brings-new-hope-to-lymphoma-patients/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:58+08:00 CAR-T cell Therapy in China: Carteyva brings new hope to lymphoma patients https://terapiyacart.com/carteyva-relmacabtagene-autoleucel-offers-long-term-benefits-with-a-single-infusion/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:58+08:00 Carteyva (Relmacabtagene Autoleucel) offers long-term benefits with a single infusion https://terapiyacart.com/better-safety-less-and-milder-side-effects-carteyva-offers-deep-remission-and-hope-for-a-cure/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:58+08:00 Better safety, less and milder side effects: Carteyva offers deep remission and hope for a cure https://terapiyacart.com/worlds-first-chinas-stomach-cancer-car-t-therapy-nears-approval-with-96-success/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:57+08:00 World’s First: China’s Stomach Cancer CAR-T Therapy Nears Approval with 96% Success https://terapiyacart.com/chinese-scientist-honored-by-nature-for-pioneering-universal-car-t-therapy-in-autoimmune-diseases/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:57+08:00 Chinese scientist honored by Nature for pioneering Universal CAR-T therapy in autoimmune diseases https://terapiyacart.com/world-first-breakthrough-off-the-shelf-car-t-therapy-shows-promise-for-autoimmune-diseases/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:57+08:00 World-first breakthrough: Off-the-shelf CAR-T therapy shows promise for autoimmune diseases https://terapiyacart.com/real-world-study-confirms-efficacy-and-safety-of-relma-cel-in-relapsed-refractory-cns-lymphoma/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:57+08:00 Real-World Study Confirms Efficacy and Safety of Relma-cel in Relapsed/Refractory CNS Lymphoma https://terapiyacart.com/dual-target-car-t-cell-therapy-shows-promise-in-slowing-aggressive-brain-tumors/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:56+08:00 Dual-Target CAR-T Cell Therapy Shows Promise in Slowing Aggressive Brain Tumors https://terapiyacart.com/allogeneic-cd19-targeted-car-t-cells-achieve-durable-remission-in-refractory-systemic-lupus-erythematosus/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:56+08:00 Allogeneic CD19-Targeted CAR-T Cells Achieve Durable Remission in Refractory Systemic Lupus Erythematosus https://terapiyacart.com/carteyva-a-promising-car-t-therapy-for-follicular-lymphoma/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:56+08:00 CARTEYVA: A promising CAR-T therapy for follicular lymphoma https://terapiyacart.com/a-new-hope-for-multiple-myeloma-understanding-bcma-car-t-therapy/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:56+08:00 A new hope for multiple myeloma: Understanding BCMA CAR-T therapy https://terapiyacart.com/fucaso-for-multiple-myeloma-car-t-therapy-testimonial-thanyaphat/ 2026-08-28T12:56:29+08:00 ru 2026-08-28T12:55:56+08:00 FUCASO for multiple myeloma, CAR-T therapy testimonial, Thanyaphat https://terapiyacart.com/understanding-in-vivo-car-t-cell-therapy-a-new-frontier-in-cancer-treatment/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:55+08:00 Understanding In Vivo CAR-T Cell Therapy: A New Frontier in Cancer Treatment https://terapiyacart.com/hicara-chinas-home-grown-cd19-car-t-cell-therapy-approved-for-lymphoma/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:55+08:00 Hicara: China’s home-grown CD19 CAR-T cell therapy approved for lymphoma https://terapiyacart.com/carteyva-relma-cel-car-t-cell-therapy-offers-new-hope-for-elderly-patients-with-relapsed-refractory-dlbcl/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:55+08:00 Carteyva (relma-cel) CAR-T cell therapy offers new hope for elderly patients with relapsed/refractory DLBCL https://terapiyacart.com/chinese-expert-consensus-2025-t-cell-immunotherapy-in-treatment-of-aggressive-b-cell-lymphoma/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:55+08:00 Chinese expert consensus 2025: T-cell immunotherapy in treatment of aggressive B-cell lymphoma https://terapiyacart.com/car-t-therapy-brings-new-hope-for-rare-lymphoma-complicated-with-autoimmune-disease/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:54+08:00 CAR-T Therapy Brings New Hope for Rare Lymphoma Complicated With Autoimmune Disease https://terapiyacart.com/bcma-car-t-therapy-in-china-shows-breakthrough-potential-in-multiple-sclerosis/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:54+08:00 BCMA CAR-T Therapy in China Shows Breakthrough Potential in Multiple Sclerosis https://terapiyacart.com/alans-car-t-cell-therapy-journey-in-china/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:54+08:00 Alan’s CAR-T Cell Therapy Journey in China https://terapiyacart.com/carteyva-china-made-car-t-cell-immunotherapy-brings-new-hope-of-cure-for-patients-with-relapsed-refractory-lymphoma/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:54+08:00 Carteyva: China-made CAR-T Cell Immunotherapy Brings New Hope of Cure for Patients with Relapsed/Refractory Lymphoma https://terapiyacart.com/beyond-cancer-and-autoimmune-diseases-what-other-diseases-can-car-t-treat-in-the-future/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:54+08:00 Beyond Cancer and Autoimmune Diseases: What Other Diseases Can CAR-T Treat in the Future? https://terapiyacart.com/inati-cel-yorwida-demonstrates-promising-efficacy-and-safety-in-adult-b-all-patients-with-post-transplant-relapse/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:53+08:00 Inati-cel (Yorwida) Demonstrates Promising Efficacy and Safety in Adult B-ALL Patients with Post-Transplant Relapse https://terapiyacart.com/cd7-car-t-therapy-for-relapsed-refractory-t-cell-lymphoma-a-single-arm-open-label-phase-i-study/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:53+08:00 CD7 CAR-T Therapy for Relapsed/Refractory T-Cell Lymphoma: A Single-Arm, Open-Label Phase I Study https://terapiyacart.com/efficacy-and-safety-of-inaticabtagene-autoleucel-for-b-all-in-china-insights-from-a-real-world-study/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:53+08:00 Efficacy and Safety of Inaticabtagene Autoleucel for B-ALL in China: Insights from a Real-World Study https://terapiyacart.com/cd19-cd20-dual-target-car-t-therapy-delivers-durable-responses-with-manageable-safety-in-relapsed-refractory-b-cell-lymphoma/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:52+08:00 CD19/CD20 Dual-Target CAR-T Therapy Delivers Durable Responses With Manageable Safety in Relapsed/Refractory B-Cell Lymphoma https://terapiyacart.com/annual-review-nmpa-approved-car-t-cell-therapies-for-hematologic-malignancies-in-2025/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:52+08:00 Annual Review | NMPA-Approved CAR-T Cell Therapies for Hematologic Malignancies in 2025 https://terapiyacart.com/real-world-evidence-yorwida-car-t-therapy-improves-outcomes-in-adult-b-all-with-high-risk-genetics/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:52+08:00 Real-World Evidence: Yorwida CAR-T Therapy Improves Outcomes in Adult B-ALL with High-Risk Genetics https://terapiyacart.com/car-t-cell-therapy-and-transplantation-evolving-strategies-for-deep-remission/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:52+08:00 CAR-T Cell Therapy and Transplantation: Evolving Strategies for Deep Remission https://terapiyacart.com/dual-target-bcma-cd19-car-t-therapy-demonstrates-durable-remission-and-long-term-safety-in-systemic-lupus-erythematosus/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:51+08:00 Dual-Target BCMA-CD19 CAR-T Therapy Demonstrates Durable Remission and Long-Term Safety in Systemic Lupus Erythematosus https://terapiyacart.com/alternative-car-t-cell-therapy-option-for-multiple-myeloma-you-should-know/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:51+08:00 Alternative CAR-T Cell Therapy Option for Multiple Myeloma You Should Know https://terapiyacart.com/eque-cel-fucaso-enables-durable-remission-in-a-multiple-myeloma-patient-relapsed-after-two-transplants/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:51+08:00 Eque-cel (Fucaso) Enables Durable Remission in a Multiple Myeloma Patient Relapsed After Two Transplants https://terapiyacart.com/study-insight-tumor-burden-reduction-may-be-key-to-improving-car-t-outcomes-in-lymphoma/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:50+08:00 Study Insight: Tumor Burden Reduction May Be Key to Improving CAR-T Outcomes in Lymphoma https://terapiyacart.com/cd19-car-t-therapy-offers-long-term-survival-hope-for-b-all-patients-relapsing-after-allo-hsct/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:50+08:00 CD19 CAR-T Therapy Offers Long-Term Survival Hope for B-ALL Patients Relapsing After Allo-HSCT https://terapiyacart.com/carteyva-car-t-therapy-in-china-offers-a-new-strategy-for-relapsed-refractory-mantle-cell-lymphoma/ 2026-08-28T12:56:28+08:00 ru 2026-08-28T12:55:50+08:00 Carteyva CAR-T Therapy in China Offers a New Strategy for Relapsed/Refractory Mantle Cell Lymphoma https://terapiyacart.com/gastric-cancer-66-7-tumor-reduction-and-durable-60-week-complete-remission/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:49+08:00 Gastric Cancer: 66.7% Tumor Reduction and Durable 60-Week Complete Remission https://terapiyacart.com/first-solid-tumor-car-t-therapy-enters-csco-gastric-cancer-guidelines-2026-a-defining-moment-for-clinical-practice/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:49+08:00 First Solid Tumor CAR-T Therapy Enters CSCO Gastric Cancer Guidelines (2026): A Defining Moment for Clinical Practice https://terapiyacart.com/2026-china-car-t-breakthroughs-revolutionary-progress-in-gastric-cancer-and-solid-tumors/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:49+08:00 2026 China CAR-T Breakthroughs: Revolutionary Progress in Gastric Cancer and Solid Tumors https://terapiyacart.com/what-is-a-solid-tumor-new-treatment-options-and-the-rise-of-car-t-therapy-for-solid-tumors-in-china/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:49+08:00 What Is a Solid Tumor? New Treatment Options and the Rise of CAR-T Therapy for Solid Tumors in China https://terapiyacart.com/what-cancers-can-be-treated-with-car-t-cell-therapy/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:48+08:00 What Cancers Can Be Treated with CAR-T Cell Therapy? https://terapiyacart.com/second-line-car-t-therapy-for-lbcl-shows-lower-hematologic-toxicity-and-improved-safety-in-real-world-study/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:48+08:00 Second-Line CAR-T Therapy for LBCL Shows Lower Hematologic Toxicity and Improved Safety in Real-World Study https://terapiyacart.com/long-term-follow-up-study-identifies-ki-67-as-a-negative-prognostic-marker-for-cd19-car-t-therapy-in-r-r-b-cell-non-hodgkin-lymphoma/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:48+08:00 Long-Term Follow-Up Study Identifies Ki-67 as a Negative Prognostic Marker for CD19 CAR-T Therapy in R/R B-Cell Non-Hodgkin Lymphoma https://terapiyacart.com/case-report-asct-combined-with-equecabtagene-autoleucel-bcma-car-t-cell-therapy-achieves-sustained-scr-with-mrd-negativity-in-ultra-high-risk-multiple-myeloma/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:47+08:00 Case Report: ASCT Combined with Equecabtagene Autoleucel BCMA CAR-T Cell Therapy Achieves Sustained sCR with MRD Negativity in Ultra–High-Risk Multiple Myeloma https://terapiyacart.com/study-in-china-highlights-car-t-cell-therapy-success-in-colorectal-cancer/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:47+08:00 Study in China Highlights CAR-T Cell Therapy Success in Colorectal Cancer https://terapiyacart.com/cldn18-2-a-new-beacon-of-hope-in-pancreatic-cancer-treatment/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:47+08:00 CLDN18.2: A New Beacon of Hope in Pancreatic Cancer Treatment https://terapiyacart.com/three-emerging-immunotherapies-for-multiple-myeloma-car-t-adcs-and-bispecific-antibodies/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:47+08:00 Three Emerging Immunotherapies for Multiple Myeloma: CAR-T, ADCs, and Bispecific Antibodies https://terapiyacart.com/why-people-travel-abroad-to-china-for-stomach-cancer-treatment/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:46+08:00 Why people travel abroad to China for stomach cancer treatment https://terapiyacart.com/from-remission-to-potential-cure-long-term-car-t-data-redefines-lymphoma-treatment-in-china/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:46+08:00 From Remission to Potential Cure: Long-Term CAR-T Data Redefines Lymphoma Treatment in China https://terapiyacart.com/satri-cel-demonstrates-durable-long-term-benefit-in-advanced-gastric-cancer-asco-2026-update/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:46+08:00 Satri-cel demonstrates durable long-term benefit in advanced gastric cancer: ASCO 2026 update https://terapiyacart.com/2026-eha-bcmaxgprc5d-car-t-therapy-ol-101-shows-remarkable-efficacy-in-relapsed-refractory-multiple-myeloma/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:46+08:00 2026 EHA | BCMA×GPRC5D CAR-T Therapy OL-101 Shows Remarkable Efficacy in Relapsed/Refractory Multiple Myeloma https://terapiyacart.com/cldn18-2-car-t-therapy-achieves-48-month-disease-control-and-conversion-surgery-in-advanced-gastric-cancer-with-peritoneal-metastasis/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:45+08:00 CLDN18.2 CAR-T Therapy Achieves 48-Month Disease Control and Conversion Surgery in Advanced Gastric Cancer With Peritoneal Metastasis https://terapiyacart.com/satri-cel-car-t-therapy-shows-long-term-survival-benefits-in-advanced-gastric-cancer-with-peritoneal-metastasis/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:45+08:00 Satri-cel CAR-T Therapy Shows Long-Term Survival Benefits in Advanced Gastric Cancer with Peritoneal Metastasis https://terapiyacart.com/carteyva-car-t-achieves-durable-complete-remission-in-high-risk-pod24-follicular-lymphoma/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:45+08:00 Carteyva CAR-T Achieves Durable Complete Remission in High-Risk POD24 Follicular Lymphoma https://terapiyacart.com/what-is-chimeric-antigen-receptor-car-t-cell-therapy/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:44+08:00 What is Chimeric Antigen Receptor (CAR) T-cell therapy? https://terapiyacart.com/car-t-moving-earlier-in-multiple-myeloma-a-new-treatment-landscape/ 2026-08-28T12:56:27+08:00 ru 2026-08-28T12:55:44+08:00 CAR-T Moving Earlier in Multiple Myeloma: A New Treatment Landscape